Rare variants in the genetic background modulate cognitive and developmental phenotypes in individuals carrying disease-associated variants. by Pizzo, L. et al.
   
 
 
 
 
Serveur Acade´mique Lausannois SERVAL serval.unil.ch
Author Manuscript
Faculty of Biology and Medicine Publication
This paper has been peer-reviewed but does not include the final publisher
proof-corrections or journal pagination.
Published in final edited form as:
Title: Rare variants in the genetic background modulate cognitive and
developmental phenotypes in individuals carrying disease-associated
variants.
Authors: Pizzo L, Jensen M, Polyak A, Rosenfeld JA, Mannik K,
Krishnan A, McCready E, Pichon O, Le Caignec C, Van Dijck A, Pope K,
Voorhoeve E, Yoon J, Stankiewicz P, Cheung SW, Pazuchanics D, Huber
E, Kumar V, Kember RL, Mari F, Curro´ A, Castiglia L, Galesi O, Avola E,
Mattina T, Fichera M, Mandara` L, Vincent M, Nizon M, Mercier S,
Be´ne´teau C, Blesson S, Martin-Coignard D, Mosca-Boidron AL, Caberg
JH, Bucan M, Zeesman S, Nowaczyk MJM, Lefebvre M, Faivre L, Callier
P, Skinner C, Keren B, Perrine C, Prontera P, Marle N, Renieri A,
Reymond A, Kooy RF, Isidor B, Schwartz C, Romano C et al.
Journal: Genetics in medicine : official journal of the American College of
Medical Genetics
Year: 2019 Apr
Issue: 21
Volume: 4
Pages: 816-825
DOI: 10.1038/s41436-018-0266-3
In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains
an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article.
Rare variants in the genetic background modulate cognitive and 
developmental phenotypes in individuals carrying disease-
associated variants
A full list of authors and affiliations appears at the end of the article.
Abstract
Purpose: To assess the contribution of rare variants in the genetic background toward variability 
of neurodevelopmental phenotypes in individuals with rare copy-number variants (CNVs) and 
gene-disruptive variants.
Methods: We analyzed quantitative clinical information, exome sequencing, and microarray data 
from 757 probands and 233 parents and siblings who carry disease-associated variants.
Results: The number of rare likely deleterious variants in functionally intolerant genes (“other 
hits”) correlated with expression of neurodevelopmental phenotypes in probands with 16p12.1 
deletion (n=23, p=0.004) and in autism probands carrying gene-disruptive variants (n=184, 
p=0.03) compared with their carrier family members. Probands with 16p12.1 deletion and a strong 
family history presented more severe clinical features (p=0.04) and higher burden of other hits 
compared with those with mild/no family history (p=0.001). The number of other hits also 
correlated with severity of cognitive impairment in probands carrying pathogenic CNVs (n=53) or 
de novo pathogenic variants in disease genes (n=290), and negatively correlated with head size 
among 80 probands with 16p11.2 deletion. These co-occurring hits involved known disease-
associated genes such as SETD5, AUTS2, and NRXN1, and were enriched for cellular and 
developmental processes.
Conclusion: Accurate genetic diagnosis of complex disorders will require complete evaluation 
of the genetic background even after a candidate disease-associated variant is identified.
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INTRODUCTION
Significant advances in high-throughput genomic sequencing technologies have helped to 
identify hundreds of genes as risk factors for neurodevelopmental and neuropsychiatric 
disorders, including autism, intellectual disability, schizophrenia, and epilepsy. For example, 
in 2002, only 2–3% of autism cases were explained by genetic factors, whereas current 
studies suggest that rare disruptive variants, including copy-number variants (CNVs) and 
single-nucleotide variants (SNVs), account for 10–30% of autism cases.1 Despite initial 
claims of association with a specific disorder or syndrome, several of these pathogenic 
variants show incomplete penetrance and variable expressivity.2–4 For example, the 16p11.2 
BP4-BP5 deletion (OMIM 611913) was first described in children with autism, but further 
studies on other clinical and population cohorts demonstrated that this deletion is also 
associated with intellectual disability and developmental delay (ID/DD), obesity, epilepsy, 
cardiac disease, and scoliosis, and only about 24% of cases manifest an autism phenotype.
5–7
 Phenotypic variability is not restricted to multigenic CNVs but has also been reported for 
single genes with pathogenic variants, including DISC1, PTEN, SCN1A, CHD2, NRXN1, 
FOXP2, and GRIN2B.3 While some of these effects could be due to allelic heterogeneity, 
phenotypic variability among carriers of the same molecular lesion suggests a strong role for 
variants in the genetic background.8,9 For example, in a large family described by St. Clair 
and colleagues,10 carriers of a balanced translocation disrupting DISC1 manifested a wide 
range of neuropsychiatric features, including schizophrenia, bipolar disorder, and 
depression. This phenomenon was exemplified by our delineation of a 520-kbp deletion on 
chromosome 16p12.1 (OMIM 136570), which is associated with developmental delay and 
extensive phenotypic variability.11 Interestingly, in most cases, this deletion was inherited 
from a parent who also manifested mild neuropsychiatric features, and the severely affected 
children were more likely to carry another large (>500 kbp) rare CNV. We hypothesized that 
while each pathogenic primary variant sensitizes the genome to varying extents, additional 
rare variants in the genetic background modulate the ultimate clinical manifestation.
Recent studies have identified secondary disease-associated variants that explain atypical 
clinical presentations of individuals carrying a primary variant.12–14 While these studies 
have explained phenotypic variability on a case-by-case basis, the global effect of the 
genetic background toward phenotypic variability among individuals sharing the same 
pathogenic variant has not been assessed. In this study, we evaluated 757 probands and 233 
family members carrying primary variants associated with neurodevelopmental disease (17 
rare CNVs or pathogenic variants in 301 genes). A comparison of the genetic background 
between probands and parents or siblings showed that in the presence of the same primary 
variant, variability and severity of neurodevelop-mental disease correlates with the number 
of other rare variants, suggesting a global role of the genetic background toward phenotypic 
heterogeneity.
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MATERIALS AND METHODS
Cohorts analyzed
We analyzed clinical and genetic data in five subgroups of individuals carrying a disease-
associated primary variant (Fig. 1): (1) 26 probands, 23 carrier parents and available family 
members carrying 16p12.1 deletion; (2) 53 autism probands from the Simons Simplex 
Collection (SSC) cohort who carry rare CNVs associated with syndromic and variably 
expressive genomic disorders;2 (3) 84 probands and available family members with 16p11.2 
BP4-BP5 deletion from the Simons Variation in Individuals Project (SVIP) cohort; (4) 295 
autism probands from the SSC cohort reported to carry severe de novo loss-of-function 
variants in neurodevelopmental genes;15,16 and (5) 184 probands and matched unaffected 
siblings from the SSC cohort who inherited the same rare (≤0.1% frequency) loss-of-
function or likely damaging missense primary variants (CADD ≥25) in genes recurrently 
disrupted in neurodevelopmental disorders.17
Patient recruitment and clinical data ascertainment
We obtained clinical and/or genomic data from 141 children carrying the 16p12.1 deletion, 
as well as 39 deletion carrier and 30 noncarrier parents. Probands and parents recruited 
through direct contact provided consent according to the protocol reviewed and approved by 
The Pennsylvania State University Institutional Review Board (IRB). When individuals were 
not contacted directly, de-identified phenotypic and genomic data were used; as such, these 
cases were exempt from IRB review and conformed to the Helsinki Declaration.
We extracted clinical information from medical records or clinical questionnaires completed 
by different physicians from 180 carrier individuals and available family members 
(Supplementary Method 1.1). We used a modified de Vries scoring system for quantifying 
the number and severity of phenotypic abnormalities in affected children, which allows for a 
uniform assessment of developmental phenotypes from clinical records (Table S1).18 Family 
history information was used to bin families with the deletion into strong and mild or 
negative family history categories based on the severity of neurodevelopmental or 
psychiatric features (Fig. S1, Supplementary Method 1.1). Genomic and clinical data for 
SSC and SVIP cohort families were obtained from the Simons Foundation Autism Research 
Initiative (SFARI) following appropriate approvals (see Supplementary Method 1.1).
Burden analysis of rare variants in the genetic background (“other hits”)
To identify all coding variants modulating the presentation of the 16p12.1 deletion, we 
performed exome sequencing and single-nucleotide polymorphism (SNP) arrays on 105 
individuals from 26 families as previously reported (Supplementary Method 1.2). Variant 
calls (SNVs and CNVs) from 716 individuals in the SSC were obtained from exome and 
SNP microarray studies,15,16,19 and variant call files (VCF) and SNP array data from 84 
families with 16p11.2 BP4-BP5 deletion were obtained from the Simons Foundation. We 
defined “rare variants” or “other hits” as additional rare likely deleterious variants (includes 
≤0.1% frequency CNV or SNV with CADD ≥25) (ref.20) affecting a functionally intolerant 
gene (RVIS ≤20th percentile) co-occurring in an individual who already carries a disease-
associated primary variant (Fig. 1a, Supplementary Method 1.2). The Residual Variation 
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Intolerance Score (RVIS) has been shown to be a good predictor of gene intolerance to 
deleterious variants and has been widely used by multiple studies for the recapitulation of 
known and the discovery of novel disease-associated genes.16,21 The biological function of 
genes with other hits was analyzed using Ingenuity Pathway Analysis (IPA, Qiagen 
Bioinformatics), expression data derived from the GTEx consortium,22 and Gene Ontology 
(GO) enrichment analysis23 (Supplementary Method 1.3).
RESULTS
Rare variants in the genetic background and disease expressivity in 16p12.1 deletion 
probands
We assessed how rare likely deleterious variants in the genetic background can modulate 
phenotypes in concert with a primary variant by evaluating 757 affected probands and 233 
family members carrying disease-associated variants (rare CNVs or pathogenic SNVs) (Fig. 
1, see Methods). Using the 16p12.1 deletion as a paradigm for studying the genetic basis of 
variable expression of disease traits, we analyzed 180 individuals with the deletion and their 
noncarrier family members (Fig. 1b). The 16p12.1 deletion was inherited in 92.4% of cases, 
with a significant maternal bias (57.6% maternal [n=53] vs. 34.8% paternal [n=32], one-
tailed binomial test p=0.01) (Table S2). In accordance with the female protective model 
described for neurodevelopmental disorders,2,24,25 we observed a significant gender bias 
among probands with the 16p12.1 deletion (67.9% males vs. 32.1% females, one-tailed 
binomial test p<0.0001). Detailed clinical analysis of 141 affected children with 16p12.1 
deletion showed a wide heterogeneity of phenotypes, with a high prevalence of 
neurodevelopmental, craniofacial, and musculoskeletal features (>50%), and variable 
involvement of other organs and systems (Fig. 2a, Table S3). In contrast, 32 of 39 (82%) 
(61.5% females, 38.5% males) carrier parents showed mild cognitive, behavioral, and/or 
psychiatric features (Table S4), consistent with previous reports of cognitive impairment and 
increased risk for schizophrenia in carriers of the 16p12.1 deletion.26,27
To identify variants within protein-coding regions that contribute to a more severe 
manifestation of the deletion in the affected children compared with their carrier parents, we 
performed exome sequencing and high-resolution SNP arrays in 26 families (n=105) with 
16p12.1 deletion (23 inherited and 3 de novo cases, Table S5). We first evaluated whether 
the deletion could unmask recessive alleles, and found no rare pathogenic variants within the 
seven 16p12.1 genes on the nondeleted chromosome (Table S6). We next performed a case-
by-case analysis of families for other hits elsewhere in the genome by focusing on rare 
CNVs (≤0.1%, ≥50 kbp), de novo or rare (ExAC frequency ≤0.1%) loss-of-function (LoF) 
variants, and rare likely damaging missense variants (Phred-like CADD ≥25) in disease-
associated genes (see Methods, Tables S7–S9). For example, we identified two disease-
associated variants in proband P1C_01, including a de novo LoF variant in the intellectual 
disability–associated gene SETD5 (OMIM 615761, c.1623_1624insAC, p. Asp542Thrfs*3) 
and a LoF variant in DMD (OMIM 310200, c.9G>A, p.Trp3X) transmitted from the 
non-16p12.1-deletion carrier mother (Fig. 2b). Similarly, a rare deletion at 2p16.3 
encompassing NRXN1 (OMIM 614332), inherited from the noncarrier mother, was 
identified in proband PC_11 (Fig. 2b).
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While private disease-associated variants may explain the variable and severe features in the 
affected children on a case-by-case basis, we lacked the statistical power to implicate 
individual genes or variants that modulate specific 16p12.1 deletion phenotypes. Therefore, 
to globally assess the genome-wide contribution of rare likely deleterious variants affecting 
functionally relevant genes, we performed an integrative analysis and quantified rare 
(frequency ≤0.1%), likely deleterious variants (CNVs or SNVs with CADD ≥25) within 
genes intolerant to functional variation (RVIS ≤20th percentile),16,20,21 hereafter referred to 
as the “burden of other hits.” Intrafamilial comparison showed that probands have an excess 
of other hits compared with their carrier parents (Wilcoxon signed-rank test, p=0.004, Fig. 
2c and S2), with no change in the number of synonymous variants in all genes (p=0.29) or in 
RVIS ≤20th genes (p=0.36, Fig. S2E, F). Further, functional analysis of genes with other hits 
showed that probands presented an excess of genes that were preferentially expressed in the 
human brain (Wilcoxon signed-rank test, p=0.04, Fig. S3) and enriched for developmental 
pathways (Table S10) compared with carrier parents.
The severity and variability of neurodevelopmental features is contingent upon family 
history of neuropsychiatric disease.25 In fact, the cognitive and social outcomes in probands 
with de novo 16p11.2 BP4-BP5 deletion or 22q11.2 deletions have been reported to 
positively correlate with the cognitive and social skills of their parents.28,29 However, the 
genetic basis of such background effects has not been specifically studied. We assessed the 
role of other hits toward family-specific background effects and in the observed interfamilial 
variability of clinical features in probands with 16p12.1 deletion. We found that probands 
with a strong family history of neurodevelopmental and psychiatric disease presented a more 
severe and heterogeneous clinical presentation (Mann–Whitney one-tailed, p=0.04) and a 
higher burden of other hits (p=0.001) than those with mild or negative family history (Figs. 
3a–c and S4A–C). Interestingly, probands with a strong family history also showed a higher 
difference in burden compared with their carrier parents than probands with a mild family 
history (p=0.003, Fig. 3d). While we did not observe a difference in burden between carrier 
parents based on family history (p=0.68, Fig. S4B), we found that noncarrier parents with a 
strong family history presented a significantly higher burden compared with those with a 
mild family history (p=0.01, Fig. 3e). Therefore, in families with a strong history of 
neurodevelopmental and psychiatric disease, a higher number of rare variants in the genetic 
background are more likely to be transmitted to the proband from the noncarrier parent, 
potentially contributing to a more severe manifestation of the disorder. These results suggest 
a potential role for rare variants in the genetic background in modulating intra- and 
interfamilial clinical variability observed in families with the 16p12.1 deletion.
Burden of other rare variants correlates with quantitative phenotypes among individuals 
with 16p11.2 deletion and other rare pathogenic CNVs
We next assessed whether the burden of other rare variants modulates quantitative 
phenotypes in carriers of other CNVs associated with neurodevelopmental phenotypes (Fig. 
1b). In autism probands with disease-associated rare CNVs (n = 53, Table S11) from the 
Simons Simplex Cohort (SSC), we observed a modest but significant negative correlation 
(Pearson correlation, R = −0.36, p = 0.004) between the number of other hits and full-scale 
IQ (FSIQ) scores (Fig. 4a). This result held true when we separately analyzed individuals 
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carrying 16p11.2 BP4-BP5 deletion (R = −0.68, p = 0.04), but did not show statistical 
significance for 16p11.2 BP4-BP5 duplication (R = −0.34, p = 0.17), 1q21.1 duplication (R 
= −0.36, p = 0.32), or 7q11.23 duplication (R = −0.74, p = 0.17), potentially due to low 
sample sizes (Figs. 4a and S5). Interestingly, probands with disease-associated CNVs and 
intellectual disability (FSIQ <70) showed a significant increase in the number of other hits 
compared with those without intellectual disability (FSIQ ≥70, one-tailed Mann–Whitney, 
p=0.02, Fig. S6).
We further expanded our analysis by evaluating a larger set of 84 families with 16p11.2 
BP4-BP5 deletion from the Simons Variation in Individuals Project (SVIP). We observed a 
higher median number of other hits in probands carrying the 16p11.2 deletion that had 
intellectual disability (FSIQ <70, median=8) compared with those with no intellectual 
disability (FSIQ ≥70, median=7 one-tailed Mann–Whitney, p = 0.08, Fig. 4b), without a 
difference in the number of synonymous variants between the two subgroups (median of 
9957 synonymous changes for FSIQ <70 group versus 10,052 for the FSIQ ≥70 group, two-
tailed Mann–Whitney, p = 0.51, Fig. S7A). Notably, we observed only a mild negative 
correlation between the burden of other hits and FSIQ, which did not attain statistical 
significance (Pearson correlation, R = −0.16, p = 0.08, Fig. S7B). Even though the sample 
size in the SSC cohort (n = 8) is small, we hypothesized that this marginal significance 
compared with 16p11.2 deletion pro-bands from the SSC cohort (Figs. 4a and S5B) could be 
due to differences in clinical ascertainment. The SVIP cohort was selected for individuals 
carrying a 16p11.2 deletion who manifested a more heterogeneous set of phenotypes, while 
individuals from the SSC cohort were specifically ascertained for idiopathic autism.30 These 
differences in ascertainment were evident by different distributions of quantitative 
phenotypes, including body mass index (BMI), FSIQ, and SRS T-scores, in both populations 
(Fig. S8).
After adjusting for age to allow for full manifestation of the head phenotype, we identified a 
negative correlation between the number of other hits in SVIP probands with 16p11.2 
deletion and their head circumference (HC) z-scores (age ≥12 months, n = 80, Pearson’s R = 
−0.26, p = 0.009, Fig. 4c).6,7 The observation that HC z-scores decline steadily (from >2 to 
<−2 scores) as other hits accumulate confirms that the deletion primarily leads to 
macrocephaly phenotypes, and suggests that rare variants in the genetic background could 
explain the incomplete penetrance of this phenotype among carriers of the deletion.7 We 
note that the burden of other hits did not correlate with Social Responsiveness Scale (SRS) 
T-scores or body mass index (BMI) z-scores, measures for autism and obesity, among 
probands with rare CNVs from the SSC cohort (Fig. S9A, B) or those with 16p11.2 deletion 
from the SVIP cohort (Fig. S9C, D), suggesting other mechanisms for the variability of 
these phenotypes.
Rare variants in the genetic background modulate disease manifestation among 
individuals with disruptive variants in disease-associated genes
We next analyzed 295 autism simplex cases from the SSC cohort with previously identified 
de novo gene-disruptive variants within 271 genes,15,16 and observed a moderately negative 
correlation between the burden of other hits and FSIQ scores (Spearman’s correlation, R = 
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−0.25, p < 0.0001, Fig. 4d). Within this cohort, individuals with intellectual disability (FSIQ 
<70, n = 93) presented an enrichment of other hits compared with those without intellectual 
disability (FSIQ ≥70, n = 197) (one-tailed Mann–Whitney, p = 0.001, Fig. S10A). We did 
not observe a role for the burden of other hits in modulating BMI z-scores (Spearman’s R = 
−0.038, p = 0.27, Fig. S10B), although we did find a mild but significant positive correlation 
with SRS T-scores (Spearman’s R = 0.12, p = 0.02, Fig. S10C). Moreover, when probands 
were separated by gender, we observed a higher burden of other hits in females compared 
with males (one-tailed Mann–Whitney, p=0.02, Fig. S11). This supports the hypothesis that 
females require a higher contribution from the genetic background to reach the genetic 
threshold for pathogenesis of neurodevelopmental disease than males.25
While there is a consensus on the pathogenic role of de novo gene-disruptive variants in 
simplex families, the interpretation of inherited pathogenic variants within the same genes is 
challenging. To understand the role of the genetic background in the penetrance of inherited 
disruptive variants in disease-associated genes, we analyzed 184 pairs of autism probands 
and unaffected siblings who inherited the same pathogenic variant in genes recurrently 
disrupted in neurodevelopmental disorders (Table S12). We found a greater enrichment of 
other hits in probands compared with their unaffected siblings (Wilcoxon signed-rank test p 
= 0.03, Fig. 4e), suggesting that rare variants likely contribute to increased penetrance of 
neurodevelopmental phenotypes in children with inherited pathogenic single-gene variants. 
When we analyzed probands carrying pathogenic variants in specific neurodevelopmental 
genes, we found that the severity of cognitive deficits in individuals with damaging variants 
in SCN1A was concordant with an excess of other hits (probands with FSIQ <70, n = 8, 
median=16.5, versus those with FSIQ ≥70, n = 8, median=8.5, one-tailed Mann–Whitney, p 
= 0.02) (Fig. 4f). This observation could also explain the diversity of other phenotypes co-
occurring with the disruption of the epilepsy-associated SCN1A gene, such as motor delay 
and autism.31
Other hits involve disease-associated genes and affect core cellular and developmental 
processes
To understand how other rare variants could modulate phenotypes among probands with 
pathogenic first-hit variants, we explored the functionality of genes with other hits identified 
in all probands analyzed in our study. Overall, we identified 3197 other hits encompassing a 
diverse set of 1615 functionally intolerant genes. Of these, 40.9% (660/1615) were found to 
be extremely intolerant to loss-of-function variants (probability of loss-of-function 
intolerance [pLI] metric ≥0.9). These genes were also enriched for postsynaptic density 
genes, genes encoding FMRP targets, chromatin-associated genes, embryonically expressed 
genes, and essential genes compared with the whole genome (52% vs. 26%, Chi-squared 
test, p<0.0001).32,33 Interestingly, 44 of these genes with other hits (such as CNTNAP2, 
MBD5, SCN1A, CHD8, and AUTS2) have been recurrently associated with 
neurodevelopmental disorders17 (Fig. S12), 58 genes have been previously identified as a 
causative gene in simplex autism cases15,16 (Table S13), and 50 genes have been associated 
with skeletal, muscular, cardiovascular, or renal disorders, as classified in the human disease 
network (Table S14).34 We further assessed the location of other-hit variants within a subset 
of genes recurrently associated with disease, including RIMS1, DIP2A, KDM5B, and 
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ACOX2, and found no specificity for the location of the other hits within the protein 
sequences compared with previously reported de novo pathogenic variants within these 
genes (Fig. 5a). In fact, in some cases, we observed stopgain variants that were more 
premature in the protein sequence than previously reported pathogenic variants, suggesting 
that the other hit can potentially exert as severe an effect as a primary variant, if these are 
true loss-of-function variants. The allelic diversity of other likely deleterious variants within 
these genes suggests that further functional analysis should be performed to understand their 
specific effects on modulating developmental phenotypes.
To further understand the functional role of genes carrying rare variants, we performed Gene 
Ontology enrichment analysis of genes with other hits in probands with de novo pathogenic 
variants from the SSC and 16p11.2 deletion probands from the SVIP cohort. We found that 
genes carrying other hits in probands from both cohorts were enriched for core processes, 
including cell signaling, cell adhesion, and developmental processes (Fig. 5b, c, Tables S15, 
S16). Although some of these genes have been individually associated with a disease 
phenotype, further functional analyses are required to understand potential interactions 
between genes affected by both primary variants and other hits, their cumulative burden, and 
ultimately their potential contribution toward phenotypic variability.
DISCUSSION
In this study, we have explored the contribution of rare variants in the genetic background 
toward the phenotypic heterogeneity of disease-associated variants. Recently, exome and 
genome sequencing studies have reported an increased burden of rare deleterious variants 
toward risk for neurodevelopmental disorders16,35,36 and combined parent-of-origin 
inherited risk effects for autism.16,32,37 Our analysis supports a complex model for 
neurodevelopmental disorders, and further postulates how rare variants in the genetic 
background modulate specific phenotypes in the presence of the same disease-causing 
variant.2,11–14 We propose that a higher burden of rare variants increases the likelihood of 
involving a modifier gene within disease-related pathways, as well as allows for a higher 
number of oligogenic combinations potentially modulating the phenotype associated with 
the first hit. Some primary variants more tolerant to changes in the genetic background, such 
as the 16p12.1 deletion, are transmitted through generations and only surpass the threshold 
for severe disease with the accumulation of several additional rare pathogenic variants. Other 
primary variants that are often de novo, such as the 16p11.2 deletion, push the genetic 
background closer to the threshold for severe manifestation and therefore require a lesser 
contribution from other hits. Similarly, highly penetrant syndromic CNVs such as Smith–
Magenis syndrome and Sotos syndrome, which are mostly de novo and encompass genes 
more intolerant to functional variation compared with variably expressive CNVs (p=0.03, 
one-tailed Mann–Whitney, Table S17, Fig. S13), would push the genetic liability beyond the 
threshold for severe disease on their own.2,11 While additional variants may not be necessary 
for complete penetrance of these disorders, these variants can modify specific phenotype 
traits when present. For example, deleterious variants in histone modifier genes have been 
reported to contribute to heart defects in 22q11.2 deletion syndrome.38 This model would 
also apply for single-gene disorders, where other hits potentially explain discordant clinical 
features reported among affected carriers of the same molecular alteration, as described for 
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Rett syndrome and individuals with pathogenic variants in the intellectual disability gene 
PACS1.39,40
Our observations that probands with a strong family history exhibit severe clinical 
manifestation and a higher burden of other hits also provide insights into the role of rare 
variants in the genetic background toward the reported correlation between parental profiles 
and clinical outcome in probands carrying rare CNVs.28,29 Moreover, the observed higher 
burden of other hits in the noncarrier parents in families with strong family history suggests 
assortative mating, and transmission of these hits to the proband potentially explains the 
increased clinical severity. Similarly, in 16p11.2 deletion, we observed that children who 
inherited the CNV presented lower FSIQ scores (n=8, median FSIQ=75) than probands with 
a de novo deletion (n=57, median FSIQ=85, one-tailed Mann–Whitney, p=0.006, Fig. 
S14A), in agreement with previous reports.6 This was also consistent with a nonsignificant 
excess of other hits among probands with an inherited 16p11.2 deletion (one-tailed Mann–
Whitney, p=0.06, Fig. S14B) compared with probands with a de novo deletion. These results 
highlight the importance of eliciting family history of psychiatric and neurodevelopmental 
disease for more accurate diagnostic assessment of the affected children.
Overall, our results suggest a multidimensional effect of rare variants in the genetic 
background toward clinical features, and their contribution to specific phenotypic domains 
depends on the extent to which the primary variant sensitizes an individual toward a specific 
phenotypic trajectory. An important observation from our study is that a large number of 
disease-associated variants deemed to be solely causative for the disorder are in fact 
accompanied by a substantial amount of rare genetic variation. Longitudinal and quantitative 
phenotyping across multiple developmental domains in all family members, along with 
genome sequencing studies in affected and seemingly asymptomatic individuals with a 
primary variant, are necessary for a more accurate understanding of these complex disorders. 
Therefore, it is critical that even after identifying a likely diagnostic pathogenic variant, 
further analysis of the genetic background must be performed to provide appropriate 
counseling and management.
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Fig. 1. Strategy for understanding the role of the genetic background in phenotypic variability of 
neurodevelopmental disease.
(a) Schematic of primary variants and other hits used in this study. Disease-associated 
variants shared among different individuals were considered as “primary variants” (blue 
box), and rare likely deleterious single-nucleotide variants (SNVs) or copy-number variants 
(CNVs) affecting functionally intolerant genes were defined as “other hits” (blue Xs). 
Individuals with a higher burden of other hits (in red) exhibit a more severe clinical 
manifestation compared with those carrying the same primary variant but with a lower 
number of other hits (in gray). (b) Combined clinical and genomic analysis of 757 probands 
and 233 family members carrying primary disease-associated variants (16p12.1 deletion, 
16p11.2 deletion, 16 rare CNVs, de novo pathogenic variants in autism simplex cases, and 
inherited pathogenic variants in disease-associated genes) was performed to understand the 
role of rare (≤0.1%) likely deleterious variants (SNVs with CADD ≥25 and CNVs) in 
functionally intolerant genes (Residual Variation Intolerance Score [RVIS] ≤20th percentile) 
toward the variable manifestation of neurodevelopmental disease. SRS Social 
Responsiveness Scale
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Fig. 2. Rare variants in the genetic background contribute to the phenotypic heterogeneity in 
16p12.1 deletion.
(a) Phenotypic spectrum of 16p12.1 deletion in probands (n=141, red) and carrier parents 
(n=39, gray). Probands exhibit a spectrum of severe developmental features compared with 
the mild cognitive and psychiatric features observed in carrier parents. Features represented 
were observed in ≥5% of probands or carrier parents. (b) Example of families with inherited 
16p12.1 deletion. Family 1 (left) shows three generations carrying 16p12.1 deletion and 
multiple neurodevelopmental and psychiatric features, with the proband (P1C_01, indicated 
with arrow) carrying a de novo loss-of-function variant in SETD5 (p.Asp542Thrfs*3) and a 
stopgain variant in DMD gene (p.Trp3X) inherited from the mother without the 16p12.1 
deletion (noncarrier). Family 2 (right) shows a proband (PC_11, indicated with arrow) with 
multiple congenital and neurodevelopmental features carrying 16p12.1 deletion and 2p16.3 
deletion (encompassing NRXN1), the latter inherited from the noncarrier mother. (c) 
Analysis of rare (≤0.1%) likely deleterious variants (single-nucleotide variants with CADD 
≥25) in genes intolerant to functional variation (RVIS ≤20th percentile) in proband–carrier 
parent pairs shows that probands present a higher burden of other hits compared with their 
carrier parents (n=23, Wilcoxon signed-rank test, p=0.004). ADHD attention deficit 
hyperactivity disorder
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Fig. 3. Strong family history of neurodevelopmental and psychiatric disease is associated with an 
excess of other hits and severe phenotypic outcome in 16p12.1 deletion probands.
(a) Diagram showing phenotypic heterogeneity in 16 probands with 16p12.1 deletion 
(black=phenotype present, white=absent, gray=not assessed) and their family history of 
neurodevelopmental and psychiatric disease (red=strong, blue=mild/negative). Probands 
with strong family history (n=9) have (b) a more heterogeneous clinical manifestation 
(higher de Vries scores, one-tailed Mann–Whitney, p=0.04) and (c) a higher burden of other 
hits (one-tailed Mann–Whitney p=0.001) than those with mild or negative family history 
(n=7). (d) Probands with a strong family history exhibit a greater difference in burden of 
other hits compared with carrier parents (p=0.003). (e) Noncarrier parents from families 
with strong family history present a higher burden compared with those with mild/negative 
family history (one-tailed Mann–Whitney, p=0.01). NC Noncarrier
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Fig. 4. Burden of other hits modulates quantitative phenotypes among probands with a first-hit 
copy-number variant (CNV) or single-nucleotide variant (SNV) associated with 
neurodevelopmental disease.
(a) Negative correlation between the number of other hits and full-scale IQ (FSIQ) scores in 
individuals (n = 53) carrying 16 CNVs associated with neurodevelopmental disease (Pearson 
correlation, R = −0.36, p = 0.004). Probands with 16p11.2 deletion (red), 16p11.2 
duplication (green), 1q21.1 duplication (blue) and 7q11.23 duplication (yellow) are 
highlighted, while gray circles represent probands with other rare CNVs. (b) Higher burden 
of other hits among probands with 16p11.2 deletion and FSIQ <70 (n = 17) compared with 
probands with FSIQ ≥70 (n = 65, one-tailed Mann–Whitney, p = 0.08). (c) Negative 
correlation between the number of other hits and head circumference z-scores (age ≥12 
months, n = 80, Pearson correlation R = −0.26, p = 0.009) in probands with 16p11.2 
deletion. (d) Autism probands with de novo disruptive variants and available FSIQ scores (n 
= 290) show a moderate negative correlation (Spearman correlation coefficient, R = −0.25, p 
< 0.0001) between the number of other hits and FSIQ scores. (e) Probands present an excess 
of other hits compared with their unaffected siblings (n = 184 pairs) carrying the same 
inherited pathogenic variants (loss-of-function or damaging missense CADD ≥25) in genes 
recurrently disrupted in neurodevelopmental disease (Wilcoxon signed-rank test, p = 0.03). 
(f) Enrichment of other hits among individuals with damaging variants in SCN1A (loss-of-
function or missense CADD ≥25) and intellectual disability (one-tailed Mann–Whitney, p = 
0.02) compared with those without intellectual disability
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Fig. 5. Rare variants in the genetic background affect core biological processes and disease-
associated genes.
(a) Examples of nonspecificity in the location of other hits in protein domains compared 
with first-hits. Location of variants in the protein sequences of RIMS1, DIP2A, KDM5B and 
ACOX2, genes with other hits (green arrows) and previously reported de novo disruptive 
variants in simplex autism cases (red arrows). Genes with other hits found in (b) autism 
spectrum disorder (ASD) probands carrying de novo disruptive variants (Simons Simplex 
Cohort; SSC) and (c) probands with the 16p11.2 deletion (Simons Variation in Individuals 
Project; SVIP) are enriched in core biological processes (FDR <0.05 with Bonferroni 
correction). Clusters of enriched Gene Ontology (GO) terms for “developmental processes,” 
“cell signaling,” “cell adhesion,” and “transport” functions are present among other hits 
found in each cohort. The size of each circle represents the number of genes annotated for 
each GO term; red shading of each circle represents the FDR for enrichment of each GO 
term among genes with other hits, with darker shades indicating a lower FDR. Line 
thickness represents the number of shared genes between pairs of GO terms. FDR values of 
the enriched GO terms are detailed in Tables S15–S16. FDR False discovery rate
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